Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. The index has shown a price gain of 21.93% this year. Over the last six months, there has been a stronger performance of -10.61%. The price of NBY leaped by -8.05% during the last 30 days period. For the last 5-days stocks have improved 2.60%.
Novabay Pharmaceuticals Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $1.01 on 09/20/24 and the lowest value was $0.44 on 09/09/24.
52-week price history of NBY Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Novabay Pharmaceuticals Inc’s current trading price is -40.59% away from its 52-week high, while its distance from the 52-week low is 36.36%. The stock’s price range during this period has varied between$0.44 and $1.01. The Novabay Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 41249.0 for the day, a figure considerably higher than their average daily volume of 36100.0 over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Novabay Pharmaceuticals Inc (NBY) has experienced a quarterly rise of 1.68% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 3.50M and boasts a workforce of 14 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.5945, with a change in price of -0.0100. Similarly, Novabay Pharmaceuticals Inc recorded 123,063 in trading volume during the last 100 days, posting a change of -1.64%.
NBY’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for NBY stands at 0.24. Similarly, the long-term debt-to-equity ratio is also 0.12.
NBY Stock Stochastic Average
Novabay Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 29.15%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 38.16%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 46.49% and 39.85%, respectively.
